In addition, 6α-ethyl-23(S)-methylcholic acid (INT-777) has been identified as a specific TGR5 agonist with promising effects in treatment of glucose homeostasis disorders, vascular inflammation and atherosclerosis, neuro-inflammation and hepato-gastro-intestinal and metabolic disorders (Pellicciari et al., 2009; Guo et al., 2016). The gene discussed is GPBAR1; the disease is Other metabolic disease.